Company profile: Eiger BioPharmaceuticals
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies, including lonafarnib, an oral farnesyl-transferase inhibitor blocking Hepatitis Delta Virus replication; avexitide, a GLP-1 receptor antagonist for post-bariatric hypoglycemia and congenital hyperinsulinism; Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies; and an Expanded Access Program.
Products and services
- Lonafarnib: An oral agent that inhibits farnesyl-transferase to block Hepatitis Delta Virus replication by preventing the essential prenylation step in the virus life cycle
- Zokinvy (Lonafarnib): A lonafarnib-based therapy for Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies, aimed at reducing mortality risk in these rare conditions
- Avexitide: A GLP-1 receptor antagonist used to treat post-bariatric hypoglycemia and congenital hyperinsulinism by normalizing insulin secretion and reducing hypoglycemia episodes
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Eiger BioPharmaceuticals
Meretek Diagnostics
HQ: United States
Website
- Description: Provider of non-invasive, non-radioactive breath tests and instruments for diagnostic applications, offering BreathTek UBT and BreathTek-UBiT collection kits for qualitative detection of urease associated with Helicobacter pylori in the human stomach, supporting initial diagnosis and post-treatment monitoring of Helicobacter pylori infection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Meretek Diagnostics company profile →
rqmicro
HQ: Switzerland
Website
- Description: Provider of rapid pathogen separation and detection technology for microbial assessment of water and food, delivering accurate results. Offers rqmicro.COUNT, a portable single-cell counting instrument, a cloud solution to organize microbiology data, application support, and test kits for intact cell count, total cell count, and quantitative E. coli detection in water.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full rqmicro company profile →
iosBio
HQ: United Kingdom
Website
- Description: Provider of thermally stable oral vaccine platforms and services, offering vaccine manufacturing, distribution, and delivery. Its OraPro technology uses viral vectors to deliver capsule-based vaccines to the GI tract, enabling mucosal and systemic immunity without cold-chain storage. Products include OraPro and OraPro-Covid-19, an at-home oral vaccine targeting S and N proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full iosBio company profile →
Trimeris
HQ: United States
Website
- Description: Provider of HIV research and drug discovery, founded in 1993 in Morrisville, North Carolina, whose early work led to an entirely new class of anti-HIV drugs called fusion inhibitors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trimeris company profile →
Novan
HQ: United States
Website
- Description: Provider of nitric oxide-based therapeutics, developing deliverable nitric oxide via its NITRICIL platform and offering ZELSUVMI, a topical gel (10.3% berdazimer) approved by the U.S. FDA for treating molluscum contagiosum.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novan company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Eiger BioPharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Eiger BioPharmaceuticals
2.2 - Growth funds investing in similar companies to Eiger BioPharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Eiger BioPharmaceuticals
4.2 - Public trading comparable groups for Eiger BioPharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →